Pancreatic cancer had a 13% survival rate. Trump’s FDA just changed everything

A survival rate worth genuine cheering, filed the same day under the administration's highlight reel.

The Food and Drug Administration’s approval of an important new drug for patients with advanced pancreatic cancer represents not only a groundbreaking scientific and medical development but also a critical step forward in the Trump administration’s efforts to speed the development of innovative treatment options that can make a meaningful difference in the lives of […]

Read it at Washington Examiner ↗

← Front page